Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 6 de 6
Biomédica (Bogotá) ; 37(1): 8-10, ene.-feb. 2017.
Article in English | LILACS | ID: biblio-888437


Abstracts We report the case of a patient presenting with multiple severe electrolyte disturbances who was subsequently found to have small cell lung cancer. Upon further evaluation, she demonstrated three distinct paraneoplastic processes, including the syndrome of inappropriate antidiuretic hormone, Fanconi syndrome, and an inappropriate elevation in fibroblast growth factor-23 (FGF23). The patient underwent one round of chemotherapy, but she was found to have progressive disease. After 36 days of hospitalization, the patient made the decision to enter hospice care and later she expired.

Resumen Se reporta el caso de una paciente que ingresó al hospital para evaluación de múltiples trastornos electrolíticos y, posteriormente, se le hizo el diagnóstico de cáncer de pulmón de células pequeñas. Tras la evaluación médica, se detectaron tres síndromes paraneoplásicos: síndrome de secreción inadecuada de hormona antidiurética, síndrome de Fanconi y elevación inapropiada del factor 23 de crecimiento de fibroblastos. Se le administró quimioterapia sin éxito, por lo cual se decidió darle tratamiento paliativo y, un tiempo después, falleció.

Humans , Paraneoplastic Syndromes/etiology , Protein Precursors/physiology , Neurophysins/physiology , Vasopressins/physiology , Small Cell Lung Carcinoma/complications , Lung Neoplasms/etiology , Protein Precursors/genetics , Protein Precursors/chemistry , Neurophysins/genetics , Neurophysins/chemistry , Vasopressins/genetics , Vasopressins/chemistry , Small Cell Lung Carcinoma/pathology , Fibroblast Growth Factor-23 , Lung Neoplasms/pathology
Medicina (B.Aires) ; 75(5): 297-302, Oct. 2015. graf, tab
Article in Spanish | LILACS | ID: biblio-841516


Las neuronopatías o ganglionopatías sensitivas, o enfermedades del ganglio dorsal, representan un subgrupo de enfermedades del sistema nervioso periférico, frecuentemente asociadas a trastornos disinmunes o paraneoplásicos, y a agentes tóxicos. Los pacientes típicamente presentan ataxia temprana, pérdida de los reflejos osteotendinosos y síntomas sensitivos positivos, presentes tanto en partes proximales como distales del cuerpo. Estudiamos retrospectivamente 10 casos con un diagnóstico final de neuronopatía sensitiva. El síntoma de presentación fue el de una neuropatía sensitiva de curso subagudo en todos los casos, con parestesias en el 100% de los casos. Otras manifestaciones fueron: hipoestesia (10/10), ataxia de la marcha (8/10), síntomas autonómicos (3/10) y parestesias periorales (3/10). La electrofisiología mostró un patrón de compromiso sensitivo axonal, con respuestas motoras normales. El diagnóstico final fue neuronopatía sensitiva adquirida en todos, asociada a síndrome de Sjögren en dos, a lupus eritematoso en uno, a artritis reumatoidea en uno, a cáncer en dos (paraneoplásica) e idiopática en cuatro. En los casos paraneoplásicos, los tumores fueron un carcinoma de pulmón de células pequeñas (con anticuerpos anti-Hu positivos) y un carcinoma epidermoide de pulmón. Ocho pacientes fueron tratados con inmunoterapia, con altas dosis de metilprednisolona endovenosa y/o con inmunoglobulina endovenosa; con pobre respuesta en cuatro casos, mejoría neurológica en cinco, y sin cambios en uno. El presente trabajo muestra el patrón clinico y electrofisiológico de las neuronopatías sensitivas subagudas, y la relevancia de un tratamiento temprano.

Sensory neuronopathies or ganglionopathies, or dorsal root ganglion disorders, represent a subgroup of peripheral nervous system diseases, frequently associated with dysinmune or neoplastic disorders and with toxic agents. A degeneration of both central and peripheral sensory proyections is present. Patients typically show early ataxia, loss of deep tendon reflexes and positive sensory symptoms present both in proximal and distal sites of the body. We retrospectively studied 10 cases with a final diagnosis of sensory neuronopathy. Sensory neuropathy was the presenting symptom and the course was subacute in all cases. Paresthesias in upper limbs were a predominant manifestation (100%). Other manifestations included: hypoesthesia (10/10), gait ataxia (8/10), autonomic symptoms (3/10) and perioral paresthesias (3/10). Electrophysiology showed sensory axonal neuronal pattern, with normal motor responses. Final diagnosis was acquired sensory neuronopathy in all patients, associated with Sjögren’s syndrome in 2, with lupus erythematosus in 1, with rheumatoid arthritis in 1, with a cancer in 2 (paraneoplastic) and idiopathic in 4. In paraneoplastic cases, the tumor was small cell lung cancer in 1 (with positive anti-Hu antibodies), and epidermoid lung cancer in the other. Eight patients were treated with immunotherapy, high dose intravenous methylprednisolone and/or intravenous immunoglobulin; with poor response in 4 cases, neurologic improvement in 5, and without any change in 1 patient. The present work shows the typical clinical and electrophysiological pattern of subacute sensory neuronopathy, and the relevance of early treatment.

Humans , Male , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Ataxia/diagnosis , Ataxia/drug therapy , Carcinoma, Squamous Cell/complications , Small Cell Lung Carcinoma/complications , Lung Neoplasms/complications , Paresthesia/diagnosis , Arthritis, Rheumatoid/complications , Ataxia/complications , Sjogren's Syndrome/complications , Immunoglobulins, Intravenous/therapeutic use , Fatal Outcome , Gait Ataxia/diagnosis , Gait Ataxia/drug therapy , Anti-Inflammatory Agents/therapeutic use
Asia Oceania Journal of Nuclear Medicine and Biology. 2014; 2 (2): 131-134
in English | IMEMR | ID: emr-167757


Radionuclide therapy is widely used as an effective modality in the management of bone pain. The main indication for this treatment is symptomatic bone metastases, confirmed by bone scintigraphy. We present a case of small cell lung cancer [SCLC] stage T[4]N[2]M[1b], with a good metabolic response to systemic therapy and radiotherapy of the primary tumor and locoregional disease, which became metabolically less active and remarkably smaller in size [reduction to 1/6 of the original volume]. In spite of the good overall response, the patient developed a syndrome with severe bone pain and had progression in the bone marrow metastases, confirmed by [18]F-FDG PET/CT. The patient received [153]Sm-EDTMP treatment with a good clinical response. However, in the whole body bone scan with the therapeutic dose, there was no visual evidence of bone metastasis. Retrospectively, by drawing the region of interest, it was possible to identify one metastatic site. The possible mechanisms of the efficacy of this treatment modality, in this specific setting, are also discussed

Humans , Male , Radioisotopes , Bone Marrow Neoplasms/secondary , Pain Management , Palliative Care , Positron-Emission Tomography , Neoplasm Metastasis , Small Cell Lung Carcinoma/complications , Lung Neoplasms
Article in English | WPRIM | ID: wpr-12975


The prognosis of patients with end-stage renal disease has improved with advances in hemodialysis techniques. However, many patients who undergo hemodialysis suffer from various types of cancer. Limited data is available to guide clinical management of these patients who may have impaired renal function. Here, we report our experience with the use of irinotecan for the treatment of a hemodialysis patient with small-cell lung cancer and end-stage renal disease.

Antineoplastic Agents, Phytogenic/therapeutic use , Camptothecin/analogs & derivatives , DNA Topoisomerases, Type I/antagonists & inhibitors , Disease-Free Survival , Follow-Up Studies , Humans , Kidney Failure, Chronic/complications , Lung Neoplasms/complications , Male , Middle Aged , Renal Dialysis/methods , Small Cell Lung Carcinoma/complications